NeuCyte’s mission is to improve the lives of those affected by Central Nervous System (CNS) related disorders by developing better translatable solutions to accelerate and optimize CNS drug discovery.
Paragon Genomics develops and commercializes rapid, easy-to-use, and ultra-high multiplex PCR-based target enrichment solutions for the Next-Generation Sequencing markets.
DeepBiome develops first-in-class therapeutics through data mining of human microbiome.
Taproot develops next-generation biomaterials for aesthetic fillers and other medical applications.
Strives to address unmet need in the treatments of gout and chronic kidney diseases